Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response

• Published in: Journal of medicinal chemistry Vol. 67; no. 5; pp. 3843 - 3859
• Main Authors: Li, Wenjuan, Li, Ting, Pan, Ying, Li, Shanhe, Xu, Gang, Zhang, Zhenlei, Liang, Hong, Yang, Feng
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 14-03-2024
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.3c02227

To develop a potential theranostic metal agent to reverse the resistance of cancer cells to cisplatin and effectively inhibit tumor growth and metastasis, we proposed to design a cyclometalated iridium (Ir) complex based on the properties of the tumor environment (TME). To the end, we designed and synthesized a series of Ir­(III) 2-hydroxy-1-naphthaldehyde thiosemicarbazone complexes by modifying the hydrogen atom(s) of the N-3 position of 2-hydroxy-1-naphthaldehyde thiosemicarbazone compounds and the structure of cyclometalated Ir­(III) dimers and then investigated their structure–activity and structure–fluorescence relationships to obtain an Ir­(III) complex (Ir5) with remarkable fluorescence and cytotoxicity to cancer cells. Ir5 not only possesses mitochondria-targeted properties but also overcomes cisplatin resistance and effectively inhibits tumor growth and metastasis in vivo. Besides, we confirmed the anticancer mechanisms of Ir5 acting on different components in the TME: directly killing liver cancer cells by inducing necroptosis and activating the necroptosis-related immune response.